In the Swedish KiSel-10 clinical trial, the study participants had an average age of 78 years at the start of the study [Alehagen 2013]. Their serum selenium concentration at baseline was at a deficiency level (mean: 67.1 mcg/L).
Moreover, the low selenium status of the elderly Swedish citizens was significantly associated with relatively high mortality risk [Alehagen 2016]. Daily supplementation with 200 mcg of a selenium-enriched yeast preparation together with 200 mg of Coenzyme Q10 raised the study participants’ serum selenium levels to 210 mcg/L and reduced the risk of cardiovascular mortality [Alehagen 2022a].
The four years of joint supplementation were associated with the following positive health outcomes: